Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.62 |
| ▸ | CTSK | P43235 | 3/20 | 0.62 |
| ▸ | REN | P00797 | 6/20 | 0.56 |
| ▸ | PSEN1 | P49768 | 4/20 | 0.50 |
| ▸ | PSEN2 | P49810 | 4/20 | 0.50 |
| ▸ | APH1B | Q8WW43 | 4/20 | 0.50 |
| ▸ | NCSTN | Q92542 | 4/20 | 0.50 |
| ▸ | APH1A | Q96BI3 | 4/20 | 0.50 |
| ▸ | PSENEN | Q9NZ42 | 4/20 | 0.50 |
| ▸ | NOS3 | P29474 | 1/20 | 0.49 |
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | NOS2 | P35228 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24754846 | 1.00 | CTSS (0.62) | CTSSCTSKRENPSEN1PSEN2 | |
| SCHEMBL29184663 | 1.00 | CTSS (0.62) | CTSSCTSKRENPSEN1PSEN2 | |
| SCHEMBL22962028 | 0.91 | REN (0.56) | CTSSCTSKRENPSEN1PSEN2 | |
| SCHEMBL28069173 | 0.90 | CTSS (0.61) | CTSSCTSKRENPSEN1PSEN2 | |
| SCHEMBL24754754 | 0.90 | CTSS (0.66) | CTSSCTSKREN | |
| SCHEMBL28069172 | 0.90 | CTSS (0.61) | CTSSCTSKRENPSEN1PSEN2 | |
| SCHEMBL24754850 | 0.90 | CTSS (0.66) | CTSSCTSKREN | |
| SCHEMBL29184618 | 0.90 | CTSS (0.66) | CTSSCTSKREN | |
| SCHEMBL12706396 | 0.89 | MMP1 (0.60) | CTSSCTSKRENPSEN1PSEN2 | |
| SCHEMBL6857159 | 0.89 | REN (0.68) | CTSSCTSKRENPSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240316059-A1 | PEPTIDE DRUG CONJUGATES | ONCOPEPTIDES AB (SE) | 2024-09-26 | — | — | US | disclosed |
| EP-4355370-A1 | PEPTIDE DRUG CONJUGATES | Oncopeptides Innovation AB (SE) | 2024-04-24 | — | — | EP | disclosed |
| CN-117794580-A | Polypeptide coupling medicine | 肿瘤多肽有限公司 | 2024-03-29 | — | — | CN | disclosed |
| WO-2022263679-A1 | PEPTIDE DRUG CONJUGATES | ONCOPEPTIDES AB (SE) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022263679-A1 | PEPTIDE DRUG CONJUGATES | ONCOPEPTIDES AB (SE) | 2022-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316059-A1 | PEPTIDE DRUG CONJUGATES | MCL1, DNPEP, VIP | CTSS 99/4885CTSK 91/4885REN 2070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.